
Outset Medical (OM) Stock Forecast & Price Target
Outset Medical (OM) Analyst Ratings
Bulls say
Outset Medical Inc. has demonstrated a solid quarter characterized by stable sales, a broadening deal pipeline, and improving margins, which collectively contribute to rebuilding the company's credibility. The company reported a gross margin of 42.9%, exceeding consensus expectations significantly, bolstered by a favorable product mix and ongoing initiatives aimed at cost reduction and manufacturing efficiencies. Additionally, with a commitment to achieving a cash burn target of less than $50 million by 2025, alongside clinical advantages of the Tablo system and an underpenetrated total addressable market, Outset Medical is well-positioned for sustained growth and potential profitability.
Bears say
Outset Medical Inc has revised its full-year guidance downward by approximately $7 million, primarily due to weaker-than-expected consumable revenue and delays in enterprise deal timing. The company also reported a total revenue of $29.4 million for Q3, missing consensus estimates, with consumables representing a significant portion of sales yet experiencing order timing challenges from key customers. Furthermore, the 2026 revenue outlook of $125 million to $130 million indicates only modest growth, contributing to a negative outlook for its stock as performance continues to diverge from expectations.
This aggregate rating is based on analysts' research of Outset Medical and is not a guaranteed prediction by Public.com or investment advice.
Outset Medical (OM) Analyst Forecast & Price Prediction
Start investing in Outset Medical (OM)
Order type
Buy in
Order amount
Est. shares
0 shares